Back to top
more

CONMED (CNMD)

(Real Time Quote from BATS)

$53.36 USD

53.36
166,241

-0.12 (-0.22%)

Updated Aug 5, 2025 01:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Why Conmed (CNMD) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

CONMED Q2 Earnings & Revenues Beat Estimates, 2025 Outlook Raised

by Zacks Equity Research

CNMD reports solid second-quarter results, driven by improving sales across both segments.

Zacks Equity Research

Compared to Estimates, Conmed (CNMD) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Conmed (CNMD) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Conmed (CNMD) delivered earnings and revenue surprises of +1.77% and +0.81%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

by Zacks Equity Research

CNMD stock rides high on strong recurring revenues, margin gains, and surgical product growth despite supply and cybersecurity challenges.

Zacks Equity Research

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Conmed (CNMD) is a Top-Ranked Value Stock: Should You Buy?

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

by Zacks Equity Research

CNMD stock rides high on strong recurring revenues, margin gains, and surgical product growth despite supply and cybersecurity challenges.

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Here's Why Conmed (CNMD) is a Strong Value Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Why Conmed (CNMD) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

CNMD Stock Up On Q1 Earnings & Sales Beat, Raised 2025 Outlook

by Zacks Equity Research

CNMD reports solid first-quarter results, driven by improving sales across both segments.

Zacks Equity Research

Compared to Estimates, Conmed (CNMD) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Conmed (CNMD) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Conmed (CNMD) delivered earnings and revenue surprises of 17.28% and 2.42%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

4 Stocks to Watch as Dental Supplies Recovers Amid Tariff Headwind

by Indrajit Bandyopadhyay

Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These are CAH, MMSI, XRAY and CNMD.

Zacks Equity Research

Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

by Zacks Equity Research

CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.

Zacks Equity Research

Conmed (CNMD) Down 12.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

New Strong Sell Stocks for February 19th

by Zacks Equity Research

ACDVF, BN and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on February 19, 2024.

Zacks Equity Research

New Strong Sell Stocks for February 11th

by Zacks Equity Research

ATS, CNMD and CSX have been added to the Zacks Rank #5 (Strong Sell) List on February 11, 2025.

Zacks Equity Research

CNMD's Q4 Earnings & Sales Beat Estimates, Stock Down on Weak Outlook

by Zacks Equity Research

CONMED reports solid fourth-quarter results, fueled by strength in the General Surgery segment and continued demand for AirSeal product.

Zacks Equity Research

Here's What Key Metrics Tell Us About Conmed (CNMD) Q4 Earnings

by Zacks Equity Research

Although the revenue and EPS for Conmed (CNMD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Conmed (CNMD) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Conmed (CNMD) delivered earnings and revenue surprises of 11.67% and 1.36%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cardinal Health (CAH) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Cardinal (CAH) delivered earnings and revenue surprises of 10.29% and 0.69%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Conmed (CNMD) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.